C urrent treatment guidelines highlight the importance of lipid-lowering therapy in reducing cardiovascular risk in patients with type 2 diabetes. Statins have been shown to be effective in reducing cardiovascular risk in patients with diabetes, but they fail to address adequately the coronary risk associated with low plasma levels of high-density lipoprotein cholesterol (HDL-C) and elevated triglycerides, commonly reported in these patients. Fibrates are effective against all three components of the atherogenic dyslipidaemic profile that characterises type 2 diabetes.
Introduction
Patients with type 2 diabetes are at markedly increased risk of cardiovascular morbidity and mortality. Given that type 2 diabetes is typically associated with an atherogenic dyslipidaemic profile characterised by elevated triglycerides, low plasma levels of high-density lipoprotein cholesterol (HDL-C), and an increase in the number of small, dense low-density lipoprotein (LDL) particles which carry an increased atherogenic risk, 1 guidelines for prevention of cardiovascular disease highlight the importance of lipid-lowering therapy in reducing cardiovascular risk in patients with diabetes. [2] [3] [4] The efficacy of the statins and fibrates has been investigated in patients with a range of cholesterol values in both primary and secondary prevention settings. Some of these studies included cohorts of patients with diabetes, enabling investigation of the efficacy of treatment in this subgroup (tables 1 and 2). In addition, five studies have included only patients with type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS), 5 the Atorvastatin Study for Prevention of Coronary Heart Disease Endpoints in Non-Insulin-Dependent Diabetes Mellitus (ASPEN) and the German Diabetes and Dialysis study (4-D), 7 the Diabetes Atherosclerosis Intervention Study (DAIS) 8 and the Fenofibrate Intervention and Event Lowering in Diabetes trial (FIELD), 9 which investigated the effect of fenofibrate 200 mg daily.
Statin therapy in patients with diabetes
The statins currently represent the cornerstone of dyslipidaemia management, based on their efficacy in reducing cardiovascular risk by lowering LDL-C. A meta-analysis based on 14 prospective studies including 90,056 patients has shown that statins reduce major coronary events by 23% and major vascular events by 21% per mmol/L reduction in LDL-C. This relative risk reduction was similar among patients with diabetes (n=18,686) who were included in a subgroup analysis. 10 Despite this, there remains a residual risk of further cardiovascular events of about 70%, which may in part be due to low levels of HDL-C and elevated triglycerides. It is noteworthy that statins have relatively modest effects on components of the atherogenic dyslipidaemia characteristic of type 2 diabetes, reducing triglycerides by 15-35% and raising HDL C typically by less than 10%. 2 
Evidence from study cohorts including patients with diabetes
Three key studies [11] [12] [13] [14] [15] have provided evidence to indicate the efficacy of statins in patients with diabetes who are treated in the secondary prevention setting (table 1). In the Scandinavian Simvastatin Survival Study (4S), 11 a total of 4,444 men and women with elevated total cholesterol (5.5-8.0 mmol/L) and established coronary heart disease (CHD) were treated with simvastatin (20-40 mg/day), in addition to dietary intervention. Of these patients, 202 were identified at baseline as having diabetes. Over a median follow-up period of 5.4 years, treatment with simvastatin produced a greater reduction in the risk of major coronary events (non-fatal myocardial infarction [MI] or CHD death) in patients with diabetes compared to those without (relative risk reduction 55% vs. 32%). 12 Subsequent subgroup analysis, including patients both with pre-existing and newly diagnosed diabetes (n=483), demonstrated a significant reduction in the relative risk of major coronary events (by 42%, p=0.001) and revascularisation (48%, p=0.005). 13 There were also significant reductions in major coronary events, revascularisation, and total and REVIEW 13 The Cholesterol and Recurrent Events (CARE) trial included a subgroup of 586 patients (14.1% of the total study population) with a clinical diagnosis of diabetes. 14 Compared with patients without diabetes, patients with a diagnosis of diabetes were older, more likely to be obese, and more likely to have had a history of cardiovascular and cerebrovascular disease. Treatment with pravastatin (40 mg/day) reduced the relative risk of coronary events (CHD death, non-fatal MI, coronary artery bypass graft [CABG] and percutaneous transluminal coronary angioplasty [PTCA]) by 25% (p=0.05) and 23% (p<0.001) in patients with and without diabetes, respectively. Although the magnitude of this risk reduction was similar in the two patient groups, this translated into a greater number of events avoided among patients with diabetes as a consequence of their higher baseline risk. 14 Furthermore, in 342 patients with impaired fasting glucose (2.8-3.2 mmol/L [110-125 mg/dL]) at entry there was a 20% relative risk reduction in major coronary events associated with pravastatin treatment. 14 A total of 782 patients (9% of the total study population) with previous MI or hospitalisation for unstable angina were included in the Long-term Intervention with Pravastatin in Ischaemic Disease (LIPID) study, involving treatment with pravastatin 40 mg/day (table 1). The relative risk reduction in non-fatal MI and CHD death observed in the diabetes cohort was consistent with that observed in non-diabetes patients (19% [-10 to 41%] vs. 25% [15 to 33%]) and the total study group (24% [12 to 35%], p<0.001 vs. placebo). 15 Subsequently, three large, prospective studies [16] [17] [18] have investigated the efficacy of statin therapy in both primary and secondary intervention settings. The Heart Protection Study (HPS), the largest statin study to date, included a subgroup of 5,963 patients with type 1 or 2 diabetes (29% of the total study group) with or at high risk of cardiovascular disease. 16 Treatment with simvastatin 40 mg daily for five years was associated with a significant reduction, by about one quarter, in the first event rate for major coronary events (non-fatal MI or CHD death), stroke and revascularisation compared with placebo among patients with diabetes. For the first occurrence of any of these major vascular events, there was a 22% reduction in event rate (p<0.0001), and in 2,426 of these patients with baseline LDL cholesterol less than 3.0 mmol/L the reduction in first event rate was 27% (p=0.0007). 16 The risk reduction in major coronary events observed in patients with diabetes was similar to that of the total study group. However, the benefits of simvastatin therapy observed in patients with diabetes without prior CHD in a primary prevention setting were about twice as great as those in the secondary prevention setting (proportional reduction in major vascular events, 32.9% vs. 18.4%). 16 Thus, the HPS was the first study to provide definitive evidence that statin therapy can provide substantial reduction in the risk of major coronary and vascular events in patients with diabetes, even in the absence of pre-existing cardiovascular disease.
In contrast, findings from the other two studies, the Antihypertensive and Lipid-Lowering to Prevent Heart Attack Trial (ALLHAT-LLT) 17 and the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT), 18 failed to show a significant benefit of statin therapy on outcome in patients with diabetes. In the ALLHAT-LLT diabetes cohort (35% of the total study population, with and without prior CHD), treat-REVIEW ment with pravastatin 40 mg daily was associated with a small and non-significant decrease in the relative risk reduction for major coronary events (non-fatal MI and CHD death) of 11%, which was comparable to that observed in the total study group. 17 The lack of a significant treatment effect may have been attributable to widespread use of nonstudy statin therapy in the control group. 17 Furthermore, in the ASCOT Lipid-Lowering Arm (LLA) treatment with atorvastatin 10 mg daily in 2,532 patients with diabetes (with and without prior vascular disease) resulted in a non-significant reduction by 16% in non-fatal MI and CHD death (compared with significant reduction of 44%, p=0.0003 in patients without diabetes). 18 There was also evidence that the effect of atorvastatin was even lower in patients with metabolic syndrome. 18 It is possible that the lack of a significant treatment effect in the diabetes group may have been due to the small number of events occurring in this subgroup (38 in the atorvastatin group and 46 in the placebo group), as the study was stopped early (after a median of 3.3 years) on the recommendation of the Data Safety Monitoring Board due to a highly significant reduction by 36% (p=0.0005) in the primary end point. 18 Subsequent subgroup analysis of ASCOT-LLA demonstrated that patients with diabetes who were treated with atorvastatin had 23% fewer major cardiovascular events and procedures than the placebo group (116 [9.2%] vs. 151 [11.9%], p=0.036), although there was no significant treatment effect with respect to the reduction in coronary events (hazard ratio 0.84, 0.55-1.29, p=0.14) and stroke (hazard ratio 0.67, 0.41-1.09, p=0.66). 19 Studies performed solely in patients with diabetes CARDS included 2,838 patients with LDL-C < 4.14 mmol/L, fasting triglycerides < 6.78 mmol/L and at least one of retinopathy, albuminuria, current smoking or hypertension, who were randomised to treatment with atorvastatin 10 mg daily or placebo. 5 The study was terminated two years earlier than expected (after a median duration of follow-up of 3.9 years) as the pre-specified stopping rule for efficacy had been met, i.e. treatment with atorvastatin was associated with a significant (p=0.001) 37% risk reduction in the primary end point (acute CHD events, coronary revascularisation and stroke). Assessed separately, acute CHD events were reduced by 36%, coronary revascularisation by 31% and stroke by 48%. 5 However, ASPEN in 2,410 patients with type 2 diabetes which was reported earlier this year, failed to show a significant treatment benefit with atorvastatin 10 mg/day. 6 The primary cardiovascular end point in this study was a composite of cardiovascular death, non-fatal MI, non-fatal stroke, recanalisation, coronary artery bypass surgery, resuscitated cardiac arrest, and worsening or unstable angina requiring hospitalisation. Most patients (79%) had no prior MI or interventional procedure. After a median of four years follow-up, 13.7% of the atorvastatin group and 15.0% of the placebo group had a primary end point (hazard ratio 0.90, 95%CI 0.73-1.12). There was also no significant treatment benefit with atorvastatin in either primary or secondary prevention settings (Hazard ratio 0.97 [95%CI 0.74-1.28] and 0.82 [95%CI 0.59-1.15], respectively). 6 In part the lack of a significant effect with atorvastatin may have been due to replacement of the study treatment with usual care for all patients with an adjudicated study end point (33% of atorvastatintreated patients and 42% of the placebo patients), on the recommendation of the Data Safety Monitoring Board. 6 Furthermore, the low cardiovascular risk of patients in both primary and secondary prevention settings (incidence of cardiovascular events, 4.4% and 15.8%, respectively 6 ) may have also contributed to the lack of a significant treatment effect.
In the 4-D study, 7 a multicentre, randomised doubleblind study of 1,255 patients with type 2 diabetes on maintenance dialysis, treatment with atorvastatin 20 mg daily was associated with a non-significant 8% reduction in the primary end point (a composite of death from cardiac causes, nonfatal MI and stroke) compared with placebo, despite a 42% reduction in LDL-C. Additionally, atorvastatin treatment was associated with an increased incidence of stroke (27 vs. 13 events, p=0.04). 7
Why the variation in cardiovascular risk reduction?
While an overview of key studies indicates that statin therapy has a favourable effect on outcome, it is also clear that there is considerable variation in the extent of this treatment benefit (figure 1).
To a large degree, this variation can be attributed to differences in the baseline characteristics of the patient populations and the end points evaluated in each study. Taking patient characteristics into account, the applicability of findings in studies such as CARDS 5 to patients with diabetes who are typically seen in clinical practice may be limited. In CARDS, patients had a median duration of diabetes at entry of 7.8 years and nearly 50% of patients had evidence of microangiopathy (either retinopathy or albuminuria), glycaemic control was less than optimal (HbA 1C 7.8%), and 67% of patients were receiving blood pressure-lowering 8% ns drugs. 5 Therefore the patient population in CARDS was at substantial CHD risk (estimated 10-year coronary risk of 25%) 5 and more likely to benefit from statin therapy. It should, however, be noted that while statins reduce coronary risk, treatment does not appear to influence the coronary risk associated with a low plasma level of HDL-C, 10, 20, 21 a characteristic of the atherogenic dyslipidaemia associated with type 2 diabetes. For example in CARE, among patients with HDL-C levels < 0.85 mmol/L treated with pravastatin, the incidence of major coronary events (non-fatal MI or CHD death) was comparable to that observed among placebo group patients with HDL-C levels > 1.14 mmol/L. 22 
Role of fibrate therapy in patients with diabetes
Fibrates have established efficacy in reducing triglycerides (by up to 50%) 1, 23 and LDL-C, as well as raising HDL-C concentrations, typically by 5-15%. 1, 23 Furthermore, the fibrates have been shown to promote a shift from small, dense LDL to larger, more buoyant particles; 24, 25 the latter are less susceptible to oxidation and possess higher binding affinity for removal by the non-atherogenic LDL receptor pathway. Fibrates also have pleiotropic effects on the artery wall, influencing endothelial function and inflammation, as well as the coagulation and fibrinolytic systems. 1 Thus, the pharmacological profile of the fibrates suggests that they may prove useful in correcting the lipid abnormalities commonly observed in patients with type 2 diabetes and metabolic syndrome.
Initial evidence suggesting a treatment benefit with fibrate therapy was provided by subgroup analysis from the Helsinki Heart Study, a primary prevention study involving 4,081 men with non-HDL-C > 5.2 mmol/L. 26 Among 135 patients with evidence of type 2 diabetes at baseline, treatment with gemfibrozil 1,200 mg/day reduced the incidence of non-fatal MI and CHD death to 3.4% compared with 10.5% in the placebo group (table 2) . 27 Numbers of patients with diabetes included in these treatment arms were, however, too low to permit meaningful statistical analysis. Recent data based on 18 years' follow-up in this study show that patients in the original gemfibrozil group with both body mass index and triglyceride levels in the highest tertiles had a significant 71% lower risk reduction in CHD mortality and a 33% lower risk reduction in all-cause mortality compared with the original placebo group. Patients with dyslipidaemia related to the metabolic syndrome especially benefited from earlier initiation of treatment. 28 Subgroup analysis of VA-HIT, which enrolled a total of 2,531 men with established CHD, elevated LDL-C (> 3.63 mmol/L) and low plasma levels of HDL-C (< 1.04 mmol/L), provided clear evidence of the efficacy of fibrates in reducing coronary risk in patients with diabetes (n=769). In these patients, treatment with gemfibrozil (1,200 mg/day) was associated with a significant 32% relative risk reduction in the composite end point of CHD death, MI and stroke (p=0.004), compared with an 18% relative risk reduction in patients without diabetes (table 2) . 29 Although patients with and without diabetes had similar risk reductions in non-fatal MI (22% and 21%, respectively) which were not statistically significant, those with diabetes had significantly greater reductions in the relative risk of CHD death (by 41%, p=0.02 vs.
3% in patients without diabetes) and stroke (by 40%, p=0.046, vs.10% in patients without diabetes) (figure 2). 29 However, subgroup analysis from the Bezafibrate Infarction Prevention (BIP) study, including 516 patients with type 2 diabetes, failed to show a significant treatment benefit in terms of reduction in the risk of the composite end point of fatal or non-fatal MI and sudden death (table 2). 30 The incidence of hypertension and obesity was higher among patients enrolled in VA-HIT than those in BIP, which may partly explain the discrepancy in results between these two studies.
DAIS, which was specifically designed to investigate whether the correction of lipoprotein abnormalities typically seen in type 2 diabetes by treatment with fenofibrate 200 mg/day would influence angiographic progression of CHD, provided further evidence of the clinical benefit of fibrate therapy. 8 In patients who were treated with fenofibrate, there was significantly less progression in markers of focal coronary artery disease (i.e. minimum lumen diameter and percent stenosis), as well as a trend for less progression in mean segment diameter, a marker of diffuse disease, compared with placebo. 8 Small, dense LDL were a determinant of coronary artery disease progression and were influenced by fenofibrate treatment. 25 Although not powered to investigate treatment effects on clinical outcome, there was also a 23% reduction in clinical events in the fenofibrate group. 8 
FIELD
Promising evidence from these trials provided the rationale for a large prospective outcome study to evaluate the potential benefits of fibrate therapy in patients with type 2 diabetes. This has now been addressed by the FIELD study, 9 specifically designed to investigate whether intervention with fenofibrate could prevent cardiovascular events in patients with type 2 diabetes, with and without dyslipidaemia. Including a total of 9,795 patients with type 2 diabetes (78% without prior cardiovascular disease), 9 FIELD was the largest REVIEW Key: VA-HIT = Veterans Affairs High-density lipoprotein Intervention Trial; CHD = coronary heart disease; MI = myocardial infarction; ns = not significant S14
DIABETES AND VASCULAR DISEASE RESEARCH clinical outcome study ever conducted in patients with type 2 diabetes. FIELD has provided important new evidence demonstrating the benefits of fenofibrate therapy in reducing cardiovascular risk in patients with type 2 diabetes. 9 Key findings and implications of FIELD are discussed by Professor Zambon in this supplement.
Synopsis
Current treatment guidelines [2] [3] [4] highlight the importance of lipid-lowering therapy in reducing cardiovascular risk in patients with diabetes. Statins have been widely investigated in patients with diabetes, in both primary and secondary prevention settings. Although statins have been shown to be effective in reducing cardiovascular risk, the magnitude of the treatment benefit depends on the baseline level of risk of patients, as determined by factors such as duration of diabetes, glycaemic control and prior history of cardiovascular disease. Moreover, statins fail to abolish the coronary risk associated with a low plasma level of HDL-C, which is common in patients with diabetes.
Fibrates are effective in addressing all three components of the atherogenic dyslipidaemic profile that characterises type 2 diabetes. Data from VA-HIT have shown that improvement in diabetic dyslipidaemia is associated with clinical benefits, significantly and substantially reducing the risk of CHD death and stroke, compared with treatment effects in patients without diabetes. 29 In addition, DAIS showed that fenofibrate treatment, compared to placebo, produced significantly less progression in markers of focal coronary artery disease in patients with type 2 diabetes. 8 Together these data provided the rationale for the FIELD study, a landmark study investigating the role of fenofibrate in patients with type 2 diabetes, with and without prior cardiovascular disease.
